Send to a Friend

Your name*

Your email adress*

Your friend's email address*


Clinical Research Grant

The Clinical Research Grant supports innovative haemostatic research on patient outcomes, quality of life, and social impacts.

The maximum grant for up to one year is € 70,000.

Areas of interest include, but are not limited to:

  • Treatment options, outcome measures, and compliance
  • Epidemiology of inhibitor development, including factors relevant to susceptibility
  • Inhibitor management issues (e.g. with focus on tolerization/immunomodulation)
  • Health economic outcomes
  • Quality of care related areas including patients’ quality of life, unmet needs, and psychosocial issues associated with the disease

In order to maintain a focus on the treatment of haemophilia and other rare bleeding disorders, Access to Insight clinical research grants will not support research focused on:

  • Pathophysiology, diagnosis, and treatment of blood transmitted diseases
  • Thrombotic disorders
  • Diagnosis and treatment of von Willebrand disease
  • Products or technologies licensed or patented by competitors of Novo Nordisk

Applicants should be health care professionals providing care for haemophilia and rare bleeding disorders patients, including nurses, physiotherapists, and psychologists.

It is assumed that a maximum of 20% of the total grant can be assigned to the candidate’s institute as overhead costs.
The quality of the project idea is the main criterion for the proposal evaluation.

The conditions of the Access to Insight programme require that any additional funding for the same project from other sources (e.g. WFH, ISTH-SSC) be declared to both funding sources. We appreciate grant recipients’ cooperation in this regard.

Download or upload your application form here.

Please click here for more information about the application review process.


December 1st, 2021
Open for Applications
April 10th, 2022
Application Deadline
April-May 2022
Review and Selection
June 2022
Notification of recipient
September 2022
Funding Available



If you are interested in
receiving the Newsletter,
please sign up.